Breast cancer detection kit or device, and detection method
It is intended to provide a kit or a device for the detection of breast cancer and a method for detecting breast cancer. The present invention provides a kit or a device for the detection of breast cancer, comprising nucleic acid(s) capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting breast cancer, comprising measuring the miRNA in vitro.
1. A method for detecting breast cancer, comprising determining expression level(s) of hsa-miR-4783-3p in a sample comprising blood, serum, or plasma from a human subject using a kit comprising a nucleic acid(s), as a primer(s) for PCR, or a probe(s) for Northern blot, Southern blot, or in situ hybridization, capable of specifically binding to hsa-miR-4783-3p, wherein the determining comprises the following steps of:
(a) contacting hsa-miR-4783-3p in the sample or complementary polynucleotide(s) thereof prepared from hsa-miR-4783-3p with the nucleic acid(s);
(b) measuring an expression level of hsa-miR-4783-3p by quantitative RT-PCR using the nucleic acid(s) as the primer(s), or Northern blot, Southern blot, or in situ hybridization using the nucleic acids as the probe(s); and
(c) comparing the expression level of hsa-miR-4783-3p measured in the step (b) with a control expression level of hsa-miR-4783-3p in a control sample of a healthy subject measured in the same way as in the step (b),
wherein a lower expression level of hsa-miR-4783-3p in the sample comprising blood, serum, or plasma from the subject as compared to the control expression level is detected and is indicative that the subject has breast cancer, and
treating the subject for breast cancer or performing a diagnostic procedure on the subject, wherein the treatment comprises surgery, radiotherapy, chemotherapy or a combination thereof, and wherein the diagnostic procedure comprises mammography, ultrasonography (echo examination), CT, MRI, abdominal ultrasonography, bone scintigraphy, PET, pathological examination of breast tissue or the combination thereof.
2. A method for detecting breast cancer, comprising:
determining an expression level(s) of hsa-miR-4783-3p in a sample comprising blood, serum, or plasma from a human subject using a device comprising a nucleic acid(s), as a probe(s), capable of specifically binding to hsa-miR-4783-3p, wherein the determining comprises the following steps of:
(a) binding hsa-miR-4783-3p in the sample or cDNA thereof prepared from hsa-miR-4783-3p to the nucleic acid(s) to measure an expression level of hsa-miR-4783-3p by hybridization using the nucleic acid(s); and
(b) comparing the expression level of hsa-miR-4783-3p measured in the step (a) with a control expression level of hsa-miR-4783-3p in a control sample of a healthy subject measured in the same way as in the step (a),
wherein a lower expression level of hsa-miR-4783-3p in the sample comprising blood, serum, or plasma from the subject as compared to the control expression level is detected and is indicative that the subject has breast cancer, and
treating the subject for breast cancer or performing a diagnostic procedure on the subject, wherein the treatment comprises surgery, radiotherapy, chemotherapy or a combination thereof, and wherein the diagnostic procedure comprises mammography, ultrasonography (echo examination), CT, MRI, abdominal ultrasonography, bone scintigraphy, PET, pathological examination of breast tissue or the combination thereof.
3. The method according to claim 1 , wherein step (c) further comprises preparing a discriminant based on a formula.
4. The method according to claim 2 , wherein step (b) further comprises preparing a discriminant based on a formula.
5. The method according to claim 3 , wherein the discriminant is compared to a threshold.
6. The method according to claim 4 , wherein the discriminant is compared to a threshold.